IsoRay Announces World's First Cesium-131 Treatment for Lung Cancer Using da Vinci Robotic Surgery System

IsoRay, Inc. ISR announced another milestone, today, in the use of its proprietary Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) in mesh. Dr. Deepak Khuntia, known as one of the nation's leading thought leaders in lung and brain tumors, performed the world's first implant of Cesium-131 mesh brachytherapy in an early stage lung cancer patient using the da Vinci® Surgical System. Dr. Khuntia and the surgical team performed the surgery at El Camino Hospital in California. For many patients with stage 1 lung cancer, treatment options are severely limited. Typically, extensive surgery is performed, removing the entire cancerous lung or one of five lobes of the lung. However, this surgery is not an option for patients with limited breathing capacity and health problems that impact normal breathing. The alternative option is a limited surgical procedure to remove the tumor mass from a lobe, leaving these patients with a 20 to 40 percent chance of their cancer recurring along the surgical repair line. With Cesium-131 mesh brachytherapy, Dr. Khuntia says the odds shift in the patient's favor, "Mesh brachytherapy can dramatically reduce the recurrence rate for early-stage lung-cancer patients. With brachytherapy, recurrence is just one percent. That's a significant difference. At the same time, patients receive significantly less radiation exposure than traditional radiation." Using the da Vinci robot to implant the Cesium-131 mesh brachytherapy further reduces radiation exposure for physicians and adds a new level of safety for patients, who benefit from a smaller incision and quicker recovery. In recent published comments on Cesium-131 mesh brachytherapy, El Camino Hospital said, "Mesh brachytherapy is one of the newest forms of targeted radiation and one of the most exciting developments in oncology today. With mesh brachytherapy, patients have the benefit of getting the most targeted radiation possible, increasing their chances of keeping the cancer from recurring and decreasing the amount of damage done to their normal lungs. Targeted radiation also does not involve the many weeks of treatment required in traditional external radiation; it can be done at the time of surgery and does not involve return trips to the hospital, except for routine follow-up visits."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!